Fränce Hardtstock1, Zeki Kocaata2, Thomas Wilke3, Axel Dittmar3, Marco Ghiani3, Vasily Belozeroff4, David J Harrison4, Ulf Maywald5, Hans Tesch6. 1. Ingress-Health HWM GmbH, Alter Holzhafen 19, 23966, Wismar, Germany. fraence.hardtstock@ingress-health.com. 2. Ingress-Health HWM GmbH, Alter Holzhafen 19, 23966, Wismar, Germany. 3. IPAM e.V., University of Wismar, 23966, Wismar, Germany. 4. Amgen Inc., Thousand Oaks, CA, USA. 5. AOK PLUS, Sternplatz 7, 01067, Dresden, Germany. 6. Centrum for Hematology and Oncology, Im Prüfling 17-19, 60389, Frankfurt a. Main, Germany.
Abstract
BACKGROUND: This study analyzes the impact of skeletal-related events (SRE) on healthcare resource utilization (HCRU) and costs incurred by patients with bone metastases (BM) from solid tumors (ST), who are therapy-naïve to bone targeting agents (BTAs). METHODS: German claims data from 01/01/2010 to 30/06/2018 were used to conduct a retrospective comparative cohort analysis of BTA-naive patients with a BM diagnosis and preceding ST diagnosis. HCRU and treatment-related costs were compared in two matched cohorts of patients with and without a history of SREs, defined as pathological fracture, spinal cord compression, surgery to bone and radiation to bone. The first SRE was defined as the patient-individual index date. Conversely, for the non-SRE patients, index dates were assigned randomly. RESULTS: In total, 45.20% of 9,832 patients reported experiencing at least one SRE (n = 4444) while 54.80% experienced none (n = 5388); 2,434 pairs of SRE and non-SRE patients were finally matched (mean age: 70.87/71.07 years; females: 39.07%/38.58%). Between SRE and non-SRE cohorts, significant differences in the average number of hospitalization days per patient-year (35.80/30.80) and associated inpatient-care costs (14,199.27€/10,787.31€) were observed. The total cost ratio was 1.16 (p < 0.001) with an average cost breakdown of 23,689.54€ and 20,403.27€ per patient-year in SRE and non-SRE patients. CONCLUSION: The underutilization of BTAs within a clinical setting poses an ongoing challenge in the real-world treatment of BM patients throughout Germany. Ultimately, the economic burden of treating SREs in patients with BM from ST was found to be considerable, resulting in higher direct healthcare costs and increased utilization of inpatient care facilities.
BACKGROUND: This study analyzes the impact of skeletal-related events (SRE) on healthcare resource utilization (HCRU) and costs incurred by patients with bone metastases (BM) from solid tumors (ST), who are therapy-naïve to bone targeting agents (BTAs). METHODS: German claims data from 01/01/2010 to 30/06/2018 were used to conduct a retrospective comparative cohort analysis of BTA-naive patients with a BM diagnosis and preceding ST diagnosis. HCRU and treatment-related costs were compared in two matched cohorts of patients with and without a history of SREs, defined as pathological fracture, spinal cord compression, surgery to bone and radiation to bone. The first SRE was defined as the patient-individual index date. Conversely, for the non-SRE patients, index dates were assigned randomly. RESULTS: In total, 45.20% of 9,832 patients reported experiencing at least one SRE (n = 4444) while 54.80% experienced none (n = 5388); 2,434 pairs of SRE and non-SRE patients were finally matched (mean age: 70.87/71.07 years; females: 39.07%/38.58%). Between SRE and non-SRE cohorts, significant differences in the average number of hospitalization days per patient-year (35.80/30.80) and associated inpatient-care costs (14,199.27€/10,787.31€) were observed. The total cost ratio was 1.16 (p < 0.001) with an average cost breakdown of 23,689.54€ and 20,403.27€ per patient-year in SRE and non-SRE patients. CONCLUSION: The underutilization of BTAs within a clinical setting poses an ongoing challenge in the real-world treatment of BM patients throughout Germany. Ultimately, the economic burden of treating SREs in patients with BM from ST was found to be considerable, resulting in higher direct healthcare costs and increased utilization of inpatient care facilities.
Authors: R L Theriault; A Lipton; G N Hortobagyi; R Leff; S Glück; J F Stewart; S Costello; I Kennedy; J Simeone; J J Seaman; R D Knight; K Mellars; M Heffernan; D J Reitsma Journal: J Clin Oncol Date: 1999-03 Impact factor: 44.544
Authors: Alison T Stopeck; Allan Lipton; Jean-Jacques Body; Guenther G Steger; Katia Tonkin; Richard H de Boer; Mikhail Lichinitser; Yasuhiro Fujiwara; Denise A Yardley; María Viniegra; Michelle Fan; Qi Jiang; Roger Dansey; Susie Jun; Ada Braun Journal: J Clin Oncol Date: 2010-11-08 Impact factor: 44.544
Authors: G N Hortobagyi; R L Theriault; A Lipton; L Porter; D Blayney; C Sinoff; H Wheeler; J F Simeone; J J Seaman; R D Knight; M Heffernan; K Mellars; D J Reitsma Journal: J Clin Oncol Date: 1998-06 Impact factor: 44.544
Authors: M Aapro; P A Abrahamsson; J J Body; R E Coleman; R Colomer; L Costa; L Crinò; L Dirix; M Gnant; J Gralow; P Hadji; G N Hortobagyi; W Jonat; A Lipton; A Monnier; A H G Paterson; R Rizzoli; F Saad; B Thürlimann Journal: Ann Oncol Date: 2007-09-28 Impact factor: 32.976
Authors: Lee S Rosen; David Gordon; Mary Kaminski; Anthony Howell; Andrew Belch; John Mackey; Justus Apffelstaedt; Mohamad A Hussein; Robert E Coleman; Dirk J Reitsma; Bee-Lian Chen; John J Seaman Journal: Cancer Date: 2003-10-15 Impact factor: 6.860
Authors: Guy Hechmati; A Brett Hauber; Jorge Arellano; Ateesha F Mohamed; Yi Qian; Francesca Gatta; Ian Haynes; Amit Bahl; Roger von Moos; Jean-Jacques Body Journal: Support Care Cancer Date: 2014-06-18 Impact factor: 3.603
Authors: Julia Simões Corrêa Galendi; Sin Yuin Yeo; Holger Grüll; Grischa Bratke; Dennis Akuamoa-Boateng; Christian Baues; Clemens Bos; Helena M Verkooijen; Arim Shukri; Stephanie Stock; Dirk Müller Journal: Front Oncol Date: 2022-09-23 Impact factor: 5.738